Pharmaceutical compound
| Combination of | |
|---|---|
| Dexamethasone | Corticosteroid |
| Levofloxacin | Anti-infective |
| Clinical data | |
| Trade names | Levodexa |
| Routes of administration | Eye drops |
| ATC code | |
| Legal status | |
| Legal status |
|
Dexamethasone/levofloxacin, sold under the brand name Levodexa, is a fixed-dose combination medication used for the prevention and treatment of inflammation, and the prevention of infection, associated with cataract surgery. It contains dexamethasone, a corticosteroid; and levofloxacin, an anti-infective.
It was approved for medical use in Canada in December 2023.
Medical uses
Dexamethasone/levofloxacin is indicated for the prevention and treatment of inflammation, and the prevention of infection, associated with cataract surgery in adults.
References
- ^ "Regulatory Decision Summary for Levodexa". Drug and Health Products Portal. 12 December 2023. Retrieved 2 April 2024.
- "Levodexa Product information". Health Canada. 12 December 2023. Retrieved 2 April 2024.
- Rizzo S, Gambini G, De Vico U, Rizzo C, Kilian R (February 2022). "A One-Week Course of Levofloxacin/Dexamethasone Eye Drops: A Review on a New Approach in Managing Patients After Cataract Surgery". Ophthalmology and Therapy. 11 (1): 101–111. doi:10.1007/s40123-021-00435-1. PMC 8770779. PMID 34936061.
 | This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it. |